Notably, following the cessation of chemotherapy, patients treated with trastuzumab and chemotherapy who continued to receive trastuzumab beyond Week 20 up to the onset of disease progression showed a trend of overall improvement in quality of life, role functioning, and social functioning, and there was a clinically significant improvement in fatigue [ 33 ].
← all excerpts
A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab.
1
—
—